Vesugen's open-label study in 41 men reported better penile blood flow

What is Vesugen?

Vesugen is the synthetic tripeptide Lys-Glu-Asp (KED), a Khavinson-group "bioregulator" that vendors sell with general longevity and anti-aging claims.

The Khavinson group's working theory is that short peptides like Lys-Glu-Asp act as bioregulators. In that theory, they bind regulatory regions of DNA and shift gene expression toward patterns seen in younger tissue, rather than acting as receptor ligands in the conventional pharmacological sense.

Is Vesugen the same as Epithalon?

Vesugen is not Epithalon (Ala-Glu-Asp-Gly): the two come from the same institute and theoretical framework, but they are different molecules with separate citation trails.

Vendor copy treats them as interchangeable "pineal peptides." When a product page cites "the bioregulator literature" or links to Epithalon studies to support Vesugen claims, that is borrowed credibility, not evidence for this specific sequence. A separate review covers the Epithalon evidence.

What does Vesugen do in blood vessel cells?

In cultured human aortic endothelial cells, Vesugen (KED) normalized elevated endothelin-1 expression, restored connexin-mediated cell-to-cell contacts, and upregulated SIRT1 ^[2].

Those cultures included cells sourced from atherosclerotic and post-restenotic tissue ^[2]. The vascular findings are the best-described piece of the KED story. SIRT1 is a sirtuin enzyme with a long history in aging biology, which is part of why Vesugen gets filed under "longevity" rather than just "vascular."

What do animal and tissue studies of Vesugen show?

In animal tissue cultures, Vesugen stimulated expression of Ki-67, a proliferation marker that typically declines with age ^[3].

That work used tissue-specific cultures from both young and old animals, plus molecular docking simulations. KED, alongside a related peptide called D-7, stimulated Ki-67 expression, and the docking simulations placed KED at a specific site in the core promoter of the MKI67 gene ^[3].

In a 5xFAD transgenic mouse model of Alzheimer's disease, daily KED injections from two to four months of age were associated with a trend toward increased neuroplasticity, and KED combined with a second peptide (EDR) prevented loss of dendritic spines ^[1]. Molecular docking in the same paper identified binding sites across several genes tied to neurodegeneration, though the abstract attributes that gene-binding list to EDR rather than to KED itself ^[1].

In organotypic rat pineal and neuroimmunoendocrine tissue cultures, Lys-Glu-Asp increased Ki-67 (proliferation) and decreased p53 (a marker tied to apoptosis and cellular stress), with a more pronounced effect in tissue from old animals ^[5]. The same paper reported altered associative learning in a honey bee memory model ^[5].

Together, these studies form a coherent and interesting mechanistic hypothesis: a short peptide proposed to nudge endothelial and neuroendocrine-associated cells toward a younger expression pattern through defined promoter interactions. Every finding comes from isolated cells, animal tissue, or docking simulations, not from a human physiological outcome, so none shows that dosing Vesugen changes vascular aging, cognition, or sleep in a living person.

Has Vesugen been tested in humans?

Vesugen has one human study: an uncontrolled trial in which 41 elderly men with vasculogenic erectile dysfunction took Vesugen as monotherapy ^[4].

Kitachev and colleagues enrolled men whose erectile dysfunction was attributed to vasculogenic causes tied to atherosclerosis. The study reported significant improvement in main penile artery blood flow, assessed both clinically and by duplex Doppler ultrasound ^[4]. That is a real, measured hemodynamic outcome, and it is at least consistent with the vascular mechanism proposed in the cell studies.

The design had no randomization, no placebo or active comparator, and no blinding, so regression to the mean, expectation effects, and concurrent care cannot be ruled out. The trial says nothing about sleep, cognition, general "anti-aging" markers, or use in women, younger adults, or anyone without vasculogenic ED. Extending its finding to a general longevity claim is exactly the kind of leap the source material does not support.

Does Vesugen improve sleep or melatonin levels?

No cited study measured Vesugen's effect on melatonin, sleep architecture, or any human sleep outcome.

The vendor sleep, pineal, and melatonin story is partly plausible at the cell-culture level, because pineal-associated organotypic tissue responded to the peptide ^[5]. Moving from a tissue culture to a claim about human sleep is an extrapolation, not a finding.

How strong is the evidence for Vesugen?

Vesugen's evidence rates grade E, minimal: no completed randomized controlled trial exists for KED, and nearly all of the record comes from a single research group.

Strip out everything about Epithalon or about the bioregulator class in general, and the cited file for KED by name is five studies: two endothelial cell and vascular papers, one transgenic mouse paper, one organotypic culture paper, and one uncontrolled human trial in a narrow population ^[1]⁠^[2]⁠^[3]⁠^[4]⁠^[5]. That file is real but thin. It does not include a single blinded or placebo-controlled human study of anything resembling sleep, melatonin, or general aging biomarkers.

Is there an evidence-based Vesugen dose?

No cited study supports a human Vesugen dose, and the vendor protocols are unsourced convention.

The protocols repeated across vendor sites, sublingual administration held for roughly 10 to 20 minutes and cycled over 10 to 20 days per month, do not trace to any cited study, and their origin and basis are unverified. The only controlled dose figure among the cited studies is 400 mcg/kg given intraperitoneally in the 5xFAD Alzheimer's mouse model ^[1]. That is an animal research dose in a disease model, not a human protocol, and it cannot be scaled to a person by simple body-weight math.

The available summary of the human trial specifies no dose or duration ^[4], so no number can be extracted from it. Oral and sublingual bioavailability is a general concern for short synthetic tripeptides, because peptide bonds are vulnerable to gut and salivary peptidases. None of the cited studies measured Vesugen's bioavailability by any route, so any specific absorption percentage circulating online is unsourced.

Separate explainers cover why peptides can't simply be swallowed and the evidence behind peptide cycling.

Is Vesugen safe to use?

Vesugen's human safety is essentially uncharacterized: no controlled trial has systematically tracked its adverse events, dosing limits, or interactions.

Injection-site reactions are reported anecdotally rather than through any systematic pharmacovigilance, and the cited studies contain no data on interactions with other medications or peptides.

Vesugen is sold research-use-only with no US drug application, so product purity, identity confirmation, and sterility depend entirely on the individual supplier, and no cited study addresses them. The guide to reading a peptide certificate of analysis covers what a test report can confirm.

What is still unknown about Vesugen?

Vesugen has no human pharmacokinetic data: no known half-life, no measured tissue distribution, and no dose-response curve in people.

Whether the vascular and gene-expression signals seen in endothelial cell culture and animal tissue ^[2]⁠^[3] translate into any measurable benefit in a general adult population remains untested. KED is a mechanistically interesting molecule riding on one small uncontrolled human trial in a specific clinical population, wrapped in marketing language borrowed from a better-cited sibling peptide.